GANX vs PATH · rev $55.2K vs P/E 19, rev $1.61B
Gain Therapeutics Inc (GANX) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Gain Therapeutics Inc (GANX) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported GANX revenue for 2023-12-31 was $55.2K. Net income was -$22.3M. Revenue was down 60.6% from 2022-12-31 to 2023-12-31. GANX currently screens at market cap $53.0M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
GANX currently screens at market cap $53.0M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the GANX and PATH stock pages for the full models.
Not investment advice.